China Shineway Pharmaceutical GroupCSWYY 92 ROC (Joel Greenblatt) % is 80.71% as of Dec. 2025, which is 74% above its 10-year median of 46.43. GuruFocus rates CSWYY with a GF Score™ of 92/100 and a GF Value™ of $17.28. The stock has 2 warning signs investors should review. Among 975 Drug Manufacturers companies, China Shineway Pharmaceutical Group ranks better than 93.33% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. China Shineway Pharmaceutical Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 80.71%.
The historical rank and industry rank for China Shineway Pharmaceutical Group's ROC (Joel Greenblatt) % or its related term are showing as below:
CSWYY'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 26.35 Med: 46.43 Max: 105.06
Current: 104.42
During the past 13 years, China Shineway Pharmaceutical Group's highest ROC (Joel Greenblatt) % was 105.06%. The lowest was 26.35%. And the median was 46.43%.
CSWYY's ROC (Joel Greenblatt) % is ranked better than 93.33% of 975
companies
in the Drug Manufacturers industry
Industry Median: 11.44
vs CSWYY: 104.42
China Shineway Pharmaceutical Group (OTCPK:CSWYY) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Shineway Pharmaceutical Group ROC (Joel Greenblatt) % Chart
CSWYY vs ZTS, UTHR: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China Shineway Pharmaceutical Group's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Shineway Pharmaceutical Group ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Shineway Pharmaceutical Group's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where China Shineway Pharmaceutical Group's ROC (Joel Greenblatt) % falls into.
China Shineway Pharmaceutical Group ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 80.71% mean?
China Shineway Pharmaceutical Group (CSWYY) has a ROC (Joel Greenblatt) % of 80.71% as of Dec. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on China Shineway Pharmaceutical Group and its competitors. This is 74% above median its historical median of 46.43. Over the past decade, China Shineway Pharmaceutical Group's ROC (Joel Greenblatt) % has ranged from 26.35 to 105.06. According to the industry distribution chart, China Shineway Pharmaceutical Group ranks #65 out of 975 companies in the Drug Manufacturers industry, placing it in the top 6.7%.
Is China Shineway Pharmaceutical Group's ROC (Joel Greenblatt) % too high?
China Shineway Pharmaceutical Group's current ROC (Joel Greenblatt) % of 80.71% is 74% above median its 10-year median of 46.43. Over the past 10 years, this metric has ranged from a low of 26.35 to a high of 105.06. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.44. China Shineway Pharmaceutical Group's value of 80.71% is 605.5% above this industry median. Based on the distribution chart, China Shineway Pharmaceutical Group ranks #65 out of 975 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, China Shineway Pharmaceutical Group has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does China Shineway Pharmaceutical Group's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Shineway Pharmaceutical Group ranks #65 out of 975 companies for ROC (Joel Greenblatt) %. This places China Shineway Pharmaceutical Group in the top 7% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.44. China Shineway Pharmaceutical Group's value of 80.71% is 605.5% above this benchmark. Historically, China Shineway Pharmaceutical Group's own ROC (Joel Greenblatt) % has ranged from 26.35 to 105.06 over the past decade. While the company's 10-year median is 46.43 vs. the industry median of 11.44, China Shineway Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.44, based on 975 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Shineway Pharmaceutical Group's current ROC (Joel Greenblatt) % of 80.71% is 605.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on China Shineway Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Shineway Pharmaceutical Group's current ROC (Joel Greenblatt) % is 80.71%, which is 74% above median its own 10-year median of 46.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Shineway Pharmaceutical Group stock overvalued right now?
China Shineway Pharmaceutical Group (CSWYY) has a current ROC (Joel Greenblatt) % of 80.71%. The stock's GF Value™ is $17.28, compared to a current price of $19.25 — trading 11.4% above its estimated fair value. The current ROC (Joel Greenblatt) % is 80.71%, which is 74% above median its 10-year median of 46.43 and 605.5% above the Drug Manufacturers industry median of 11.44. China Shineway Pharmaceutical Group's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For China Shineway Pharmaceutical Group (CSWYY), the current ROC (Joel Greenblatt) % is 80.71% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Shineway Pharmaceutical Group (CSWYY) Overvalued in 2026?
Based on GuruFocus' analysis, China Shineway Pharmaceutical Group stock appears to be overvalued.
The current stock price of $19.25 is trading 11.4% above its estimated GF Value™ of $17.28.
Key valuation signals for CSWYY:
ROC (Joel Greenblatt) %: 80.71% (74% above median its 10-year median of 46.43)
GF Value™: $17.28 vs. price of $19.25 (11.4% above fair value)
Industry Position: 605.5% above the Drug Manufacturers median (#65 of 975)
No single metric tells the full story. See the CSWYY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Shineway Pharmaceutical Group Business Description
China Shineway Pharmaceutical Group Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, traditional Chinese medicine formula granules, and others, of which injections generate maximum revenue for the company. Geographically, the group operates in the People's Republic of China (PRC) and Hong Kong.
92GF Score
Get the complete analysis for CSWYY
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSWYY has been successfully added to your 
